Immunotherapy in Hepatocellular Carcinoma
Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of t...
Saved in:
| Format: | Online |
|---|---|
| Language: | English |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | ONIX_20230511_9783036566917_39 |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1863729660673654784 |
|---|---|
| collection | Directory of Open Access Books |
| description | Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of the art in the immunotherapy of HCC from both the basic and clinical perspectives, and outline future perspectives for improving therapies. |
| format | Online |
| id | doab-20.500.12854ir-100022 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1000222024-03-31T13:10:36Z Immunotherapy in Hepatocellular Carcinoma Nishida, Naoshi Kudo, Masatoshi cancer immunotherapy TCGA mutations copy number variations microRNAs PD-1 PD-L1 hepatocellular carcinoma predictive factors immunotherapy immune checkpoint inhibition check-point inhibitors liver disease outcome biomarkers combination immunotherapy immune-related adverse events (irAEs) hepatocellular carcinoma (HCC) alpha fetoprotein response immune checkpoint inhibitor unresectable hepatocellular carcinoma a disintegrin and metalloprotease 9 nivolumab natural killer CTLA-4 combination therapy PD-1 antibody PD-L1 antibody anti-VEGF inhibitor molecular classification immune phenotype stem cell marker oncogenic signal β-catenin genetic alteration liver cancer effectiveness safety HCC molecular-targeted agent TACE tyrosine kinase inhibitor CD14+ cells programmed death 1 ligands translational approaches combination therapies therapy resistance predictive markers tissue-resident memory CD8 T cells immune checkpoint blockade thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of the art in the immunotherapy of HCC from both the basic and clinical perspectives, and outline future perspectives for improving therapies. 2023-05-11T17:17:06Z 2023-05-11T17:17:06Z 2023 book ONIX_20230511_9783036566917_39 9783036566917 9783036566900 https://directory.doabooks.org/handle/20.500.12854/100022 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/7115 https://mdpi.com/books/pdfview/book/7115 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-6690-0 10.3390/books978-3-0365-6690-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036566917 9783036566900 276 Basel open access |
| spellingShingle | cancer immunotherapy TCGA mutations copy number variations microRNAs PD-1 PD-L1 hepatocellular carcinoma predictive factors immunotherapy immune checkpoint inhibition check-point inhibitors liver disease outcome biomarkers combination immunotherapy immune-related adverse events (irAEs) hepatocellular carcinoma (HCC) alpha fetoprotein response immune checkpoint inhibitor unresectable hepatocellular carcinoma a disintegrin and metalloprotease 9 nivolumab natural killer CTLA-4 combination therapy PD-1 antibody PD-L1 antibody anti-VEGF inhibitor molecular classification immune phenotype stem cell marker oncogenic signal β-catenin genetic alteration liver cancer effectiveness safety HCC molecular-targeted agent TACE tyrosine kinase inhibitor CD14+ cells programmed death 1 ligands translational approaches combination therapies therapy resistance predictive markers tissue-resident memory CD8 T cells immune checkpoint blockade thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Immunotherapy in Hepatocellular Carcinoma |
| title | Immunotherapy in Hepatocellular Carcinoma |
| title_full | Immunotherapy in Hepatocellular Carcinoma |
| title_fullStr | Immunotherapy in Hepatocellular Carcinoma |
| title_full_unstemmed | Immunotherapy in Hepatocellular Carcinoma |
| title_short | Immunotherapy in Hepatocellular Carcinoma |
| title_sort | immunotherapy in hepatocellular carcinoma |
| topic | cancer immunotherapy TCGA mutations copy number variations microRNAs PD-1 PD-L1 hepatocellular carcinoma predictive factors immunotherapy immune checkpoint inhibition check-point inhibitors liver disease outcome biomarkers combination immunotherapy immune-related adverse events (irAEs) hepatocellular carcinoma (HCC) alpha fetoprotein response immune checkpoint inhibitor unresectable hepatocellular carcinoma a disintegrin and metalloprotease 9 nivolumab natural killer CTLA-4 combination therapy PD-1 antibody PD-L1 antibody anti-VEGF inhibitor molecular classification immune phenotype stem cell marker oncogenic signal β-catenin genetic alteration liver cancer effectiveness safety HCC molecular-targeted agent TACE tyrosine kinase inhibitor CD14+ cells programmed death 1 ligands translational approaches combination therapies therapy resistance predictive markers tissue-resident memory CD8 T cells immune checkpoint blockade thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| topic_facet | cancer immunotherapy TCGA mutations copy number variations microRNAs PD-1 PD-L1 hepatocellular carcinoma predictive factors immunotherapy immune checkpoint inhibition check-point inhibitors liver disease outcome biomarkers combination immunotherapy immune-related adverse events (irAEs) hepatocellular carcinoma (HCC) alpha fetoprotein response immune checkpoint inhibitor unresectable hepatocellular carcinoma a disintegrin and metalloprotease 9 nivolumab natural killer CTLA-4 combination therapy PD-1 antibody PD-L1 antibody anti-VEGF inhibitor molecular classification immune phenotype stem cell marker oncogenic signal β-catenin genetic alteration liver cancer effectiveness safety HCC molecular-targeted agent TACE tyrosine kinase inhibitor CD14+ cells programmed death 1 ligands translational approaches combination therapies therapy resistance predictive markers tissue-resident memory CD8 T cells immune checkpoint blockade thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology |
| url | ONIX_20230511_9783036566917_39 |